I am a
Home I AM A Search Login

Papers of the Week

Papers: 21 Jan 2023 - 3 Feb 2023

2023 Feb 02


Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis.


Wagner F, Mansfield JC, Lekkerkerker AN, Wang Y, Keir M, Dash A, Butcher B, Harder B, Orozco LD, Mar JS, Chen H, Rothenberg ME
Gut. 2023 Feb 02.
PMID: 36732049.


The interleukin-22 cytokine (IL-22) has demonstrated efficacy in preclinical colitis models with non-immunosuppressive mechanism of action. Efmarodocokin alfa (UTTR1147A) is a fusion protein agonist that links IL-22 to the crystallisable fragment (Fc) of human IgG for improved pharmacokinetic characteristics, but with a mutation to minimise Fc effector functions.